Evolution of the polypill concept and ongoing clinical trials

Area of Science:

• Cardiovascular Medicine
• Global Health
• Pharmacotherapy

Background:

• Ischemic heart disease and stroke are leading global causes of death, increasingly prevalent in low- and middle-income countries (LMICs) due to lifestyle changes.
• Noncommunicable diseases now surpass communicable diseases as primary mortality causes in LMICs.
• A significant burden of individuals at high cardiovascular risk reside in LMICs, where most cardiovascular events occur.

Purpose of the Study:

• To examine the potential of fixed-dose combination (FDC) therapy in improving cardiovascular event prevention.
• To assess how FDC therapy can overcome barriers such as poor adherence, limited availability, and high cost of medications in LMICs.

Main Methods:

• Review of evidence supporting pharmacological interventions for cardiovascular event prevention.
• Analysis of the challenges hindering treatment efficacy in LMICs.
• Exploration of FDC therapy as a strategy to improve medication adherence, reduce costs, and enhance affordability.

Main Results:

• Pharmacological treatments like antiplatelet drugs, beta-blockers, lipid-lowering agents, and ACE inhibitors are evidence-based for prevention.
• Inadequate prescription, poor adherence, limited availability, and unaffordable costs significantly hamper treatment efficacy in LMICs.
• FDC therapy presents a promising approach to address these multifaceted challenges.

Conclusions:

• Fixed-dose combination therapy offers a viable strategy to improve cardiovascular event prevention in LMICs.
• This approach has the potential to enhance patient adherence, reduce overall treatment costs, and increase medication affordability.
• Implementing FDC therapy could significantly impact the global burden of cardiovascular disease, particularly in resource-limited settings.